Experience in using low-temperature plasma after surgical treatment of breast cancer

Abstract

Background. Plasma medicine is a new direction in science at the intersection of plasma physics and chemistry with biology and medicine low-temperature plasma (LTP) has a number of fundamental advantages, which include high non-specific bactericidal activity, low probability of the appearance of stable forms, the absence of ionizing radiation and highly toxic substances. In addition, LTP stimulates healing of infected wounds at the early stages of exposure, which makes LTP a promising method of treating various pathological conditions.

Clinical case description. Low-temperature argon plasma treatment was performed for a patient with a diagnosis of: cancer of the right breast cancer T₂N₁M₀, IIB stage. Condition after non-adjuvant PCT and radical resection of the right breast. Complication: Abscess in the area of the postoperative scar. After the 3rd treatment with plasma flow, the wound was sutured and while continuing treatment with low-temperature argon plasma, the patient began radiation therapy of the right breast and regional lymph flow zones in the mode of classical dose fractionation. During the follow-up period, the patient showed positive dynamics in the area of the postoperative scar, which did not lead to a long period of rehabilitation in the postoperative period and radiation therapy was started in a timely manner.

Conclusion. Thus, the use of this technique in clinical practice has proven that the period of rehabilitation in the postoperative period is shortened for continuous comprehensive treatment of severe cancer patients with breast cancer.

Keywords

rehabilitation / low-temperature argon plasma / complications of surgical treatment / breast cancer / radical mastectomy / radical breast resection / radiation therapy / early postoperative period

References

[1] Zhukhovitsky VG, Kazakova MV, Sysolyatina EV, et al. Bactericidal effect of low-temperature plasma against Helicobacter pylori in vitro. Experimental and Clinical Gastroenterology. 2019;(3):51-57. (In Russ). doi: 10.31146/1682-8658-ecg-163-3-51-57.

[2] Жуховицкий В.Г., Казакова М.В., Сысолятина Е.В., и др. Бактерицидный эффект низкотемпературной плазмы в отношении Helicobacter pylori in vitro // Экспериментальная и клиническая гастроэнтерология. 2019. №3. С. 51-57. doi: 10.31146/1682-8658-ecg-163-3-51-57.

[3] Isbary G, Shimizu T, Li YF, et al. Cold atmospheric plasma devices for medical issues. Expert Rev Med Devices. 2013;10(3):367-377. doi: 10.1586/erd.13.4.

[4] Isbary G., Shimizu T., Li Y.F., et al. Cold atmospheric plasma devices for medical issues // Expert Rev Med Devices. 2013. Vol. 10, N 3. P. 367-377. doi: 10.1586/erd.13.4.

[5] Sysolyatina EV. Bakteritsidnyye svoystva nizkotemperaturnoy plazmy in vitro i in vivo. [dissertation abstract] Moscow; 2013. 22 р. (In Russ).

[6] Сысолятина Е.В. Бактерицидные свойства низкотемпературной плазмы in vitro и in vivo: Автореф. дис. ... канд. биол. наук. М., 2013. 22 с.

[7] Gerasimenko MYu, Zaitseva TN, Evstigneeva IS. Low-temperature plasma — a promising method of rehabilitation. Physical and rehabilitation medicine, medical rehabilitation. 2019;3(3):79-89. (In Russ). doi: 10.36425/2658-6843-2019-3-79-89.

[8] Герасименко М.Ю., Зайцева Т.Н., Евстигнеева И.С. Низкотемпературная плазма ― перспективный метод лечения и реабилитации // Физическая и реабилитационная медицина, медицинская реабилитация. 2019. Т. 3. № 3. С. 79-89. doi: 10.36425/2658-6843-2019-3-79-89.

[9] Ermolaeva SA, Varfolomeev AF, Chernukha MY, et al. Bactericidal effects of non-thermal argon plasma in vitro, in biofilms and in the animal model of infected wounds. J Med Microbiol. 2011;60:

[10] Ermolaeva S.A., Varfolomeev A.F., Chernukha M.Y., et al. Bactericidal effects of non-thermal argon plasma in vitro, in biofilms and in the animal model of infected wounds // J Med Microbiol. 2011. Vol. 60. Pt 1. P. 75-83. doi: 10.1099/jmm.0.020263-0.

[11] (Pt 1):75-83. doi: 10.1099/jmm.0.020263-0.

[12] Welz C., Emmert S., Canis M., et al. Cold atmospheric plasma: a promising complementary therapy for squamous head and neck cancer // PLoS One. 2015. Vol. 10. N 11. P. e0141827. doi: 10.1371/journal.pone.0141827.

[13] Welz C, Emmert S, Canis M, et al. Cold atmospheric plasma: a promising complementary therapy for squamous head and neck cancer. PLoS One. 2015;10(11):e0141827. doi: 10.1371/journal.pone.0141827.

[14] Пак Д.Д., Соколов В.В., Ермощенкова М.В. Применение воздушно-плазменных потоков для профилактики лимфореи при хирургическом лечении рака молочной железы // Российский онкологический журнал. 2007. № 5. С. 29-33.

[15] Pak DD, Sokolov VV, Ermoshhenkova MV. Use of air-plasma currents to prevent lymphorrhea in the surgical treatment of breast cancer. Russian Journal of Oncology. 2007;(5):29-33. (In Russ).

[16] Патент РФ № 2334485. Пак Д.Д., Соколов В.В., Кабисов Р.К., Ермощенкова М.В. Способ профилактики лимфореи после мастэктомии. Доступно по: https://yandex.ru/patents/doc/RU2334485C1_20080927.

[17] Patent RUS № 2334485. Pak DD, Sokolov VV, Kabisov RK, Ermoshhenkova MV. Method of prevention of imparai after mastectomy. (In Russ). Available from: https://yandex.ru/patent/doc/RU2334485C1_20080927.

[18] Кабисов Р.К., Чиссов В.И., Соколов В.В., Пекшев А.В. Плазменные потоки в онкохирургии. Методические рекомендации. М., 1996. 14 с.

[19] Kabisov RK, Chissov VI, Sokolov VV, Pekshev AV. Plazmennyye potoki v onkokhirurgii. Metodicheskiye rekomendatsii. Moscow; 1996. 14 р. (In Russ).

[20] Луцевич О.Э., Тамразова О.Б., Кулешов И.Ю., и др. Воздушно-плазменные потоки в режиме коагуляции, NO-терапии в комплексном лечении длительно незаживающих и хронических ран (язв) нижних конечностей // Московский хирургический журнал. 2011. № 2. С. 9-13.

[21] Lucevich OE, Tamrazova OB, Kuleshov IYu, et al. Air-plasma flow in the mode of coagulation, NO-therapy in complex treatment of prolonged unhealed and chronic wounds (ulcer) of the lower extremities. Moscow surgical journal. 2011;(2):9-13. (In Russ).

[22] Matsumoto K., Funakoshi H., Takahashi H., Sakai K. HGFMet path¬way in regeneration and drug discovery // Biomedicines. 2014. Vol. 2.

[23] Matsumoto K, Funakoshi H, Takahashi H, Sakai K. HGFMet pathway in regeneration and drug discovery. Biomedicines. 2014;2(4):275-300. doi: 10.3390/biome dicin es204 0275.

[24] N 4. P. 275-300. doi: 10.3390/biome dicin es204 0275.

[25] Miyazawa K, Tsubouchi H, Naka D, et al. Molecular cloning and sequence analysis of cDNA for human hepatocyte growth factor. Biochem Biophys Res Commun. 1989;163(2):967-973.

[26] Miyazawa K., Tsubouchi H., Naka D., et al. Molecular cloning and sequence analysis of cDNA for human hepatocyte growth factor // Biochem Biophys Res Commun. 1989. Vol. 163. N 2. P. 967-973. doi: 10.1016/0006-291X(89)92316-4.

[27] doi: 10.1016/0006-291X(89)92316-4.

[28] Morishita R., Makino H., Aoki M., et al. Phase I/IIa clinical trial of therapeutic angiogenesis using hepatocyte growth factor gene transfer to treat critical limb ischemia // Arterioscler Thromb Vasc Biol. 2011. Vol. 31. N 3. P. 713-720. doi: 10.1161/ATVBA HA.110.219550.

[29] Morishita R, Makino H, Aoki M, et al. Phase I/IIa clinical trial of therapeutic angiogenesis using hepatocyte growth factor gene transfer to treat critical limb ischemia. Arterioscler Thromb Vasc Biol. 2011;31(3):713-720. doi: 10.1161/ATVBA HA.110.219550.

RIGHTS & PERMISSIONS

Eco-Vector